Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Agomelatine 10 mg/day or 25 mg/day versus placebo for 12 weeks in non-depressed outpatients with generalized anxiety disorder
2012-001666-15Phase 3Completed
- Sponsor
- Servier
- Start
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of agomelatine in generalized anxiety disorder (GAD) (3 arms), sponsored by Servier. Started Apr 2013; status: completed.
02
Drugs
agomelatine
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on 2012-001666-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001666-15.